Evoke Pharma, Inc. Forecasted to Earn FY2017 Earnings of ($0.65) Per Share (EVOK)
Evoke Pharma, Inc. (NASDAQ:EVOK) – Research analysts at FBR & Co issued their FY2017 earnings per share estimates for shares of Evoke Pharma in a report released on Wednesday. FBR & Co analyst D. Buck anticipates that the specialty pharmaceutical company will post earnings per share of ($0.65) for the year. FBR & Co currently has a “Buy” rating and a $10.00 target price on the stock. FBR & Co also issued estimates for Evoke Pharma’s FY2018 earnings at ($0.33) EPS, FY2019 earnings at $0.00 EPS, FY2020 earnings at $0.00 EPS and FY2021 earnings at $1.10 EPS.
Evoke Pharma (NASDAQ:EVOK) last posted its quarterly earnings results on Monday, August 14th. The specialty pharmaceutical company reported ($0.27) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.12) by ($0.15). During the same quarter in the previous year, the business earned ($0.41) EPS. TRADEMARK VIOLATION WARNING: This piece was published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this piece on another publication, it was illegally copied and republished in violation of United States and international trademark & copyright laws. The legal version of this piece can be accessed at https://www.thecerbatgem.com/2017/10/24/evoke-pharma-inc-forecasted-to-earn-fy2017-earnings-of-0-65-per-share-evok.html.
EVOK has been the topic of several other research reports. Seaport Global Securities restated a “buy” rating and issued a $10.00 price objective on shares of Evoke Pharma in a research note on Friday, October 6th. HC Wainwright restated a “buy” rating and issued a $9.00 price objective on shares of Evoke Pharma in a research note on Tuesday, August 15th. ValuEngine downgraded shares of Evoke Pharma from a “hold” rating to a “sell” rating in a research note on Friday, September 1st. Northland Securities restated a “buy” rating and issued a $10.00 price objective on shares of Evoke Pharma in a research note on Wednesday, October 18th. Finally, Zacks Investment Research upgraded shares of Evoke Pharma from a “strong sell” rating to a “hold” rating in a research note on Thursday, October 12th. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and six have assigned a buy rating to the stock. The company presently has a consensus rating of “Buy” and a consensus price target of $8.86.
Shares of Evoke Pharma (NASDAQ EVOK) opened at 3.20 on Monday. The firm’s market capitalization is $49.24 million. Evoke Pharma has a 12-month low of $1.35 and a 12-month high of $4.55. The company has a 50-day moving average of $3.37 and a 200 day moving average of $2.76.
A hedge fund recently raised its stake in Evoke Pharma stock. State Treasurer State of Michigan raised its stake in shares of Evoke Pharma, Inc. (NASDAQ:EVOK) by 37.0% in the second quarter, according to the company in its most recent disclosure with the SEC. The firm owned 400,000 shares of the specialty pharmaceutical company’s stock after acquiring an additional 108,034 shares during the quarter. State Treasurer State of Michigan owned approximately 2.60% of Evoke Pharma worth $1,024,000 as of its most recent filing with the SEC. 12.88% of the stock is owned by hedge funds and other institutional investors.
About Evoke Pharma
Evoke Pharma, Inc is a specialty pharmaceutical company. The Company is focused primarily on the development of drugs to treat gastrointestinal (GI) disorders and diseases. The Company is developing EVK-001, a metoclopramide nasal spray for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in women.
Receive News & Stock Ratings for Evoke Pharma Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evoke Pharma Inc. and related stocks with our FREE daily email newsletter.